Lilly's Omvoh shows sustained remission in Crohn's disease study

Eli Lilly and Company (NYSE: LLY) reported long-term data showing its drug Omvoh maintained steroid-free remission in patients with Crohn's disease over three years of treatment.

Data from the Phase 3 VIVID-2 open-label extension study showed 92.4% of patients who achieved endoscopic response at one year maintained clinical remission at 152 weeks. Additionally, 91.2% maintained corticosteroid-free clinical remission during the same period.

The study tracked patients who had previously achieved endoscopic response in the VIVID-1 trial and continued treatment in the extension study. Results showed 82.1% of patients experienced a reduction of at least 3 points on the Urgency Numeric Rating Scale, which measures bowel urgency severity.

Separate data from VIVID-1 and LUCENT-3 clinical trials indicated reduced hospitalization and surgery rates among Omvoh-treated patients. In VIVID-1, Crohn's disease-related hospitalizations and surgeries decreased by nearly half versus placebo in the first 12 weeks and by nearly 70% during weeks 12 to 52.

The safety profile remained consistent with previous studies. Common adverse events during the extension period included COVID-19, nasopharyngitis, and upper respiratory tract infection, affecting at least 5% of patients.

Omvoh, also known as mirikizumab-mrkz, is an interleukin-23p19 antagonist approved for treating moderately to severely active ulcerative colitis and Crohn's disease in adults. The drug has received regulatory approval in 47 countries.

Lilly is conducting combination studies of mirikizumab with other treatments and has initiated trials evaluating its use with incretin-based therapies in patients who also have obesity or weight-related conditions.

You May Also Be Interested In

• Marvell Technology (MRVL) call put ratio 1.7 calls to 1 put into SEMICON West conference
• Jefferies: India regulator proposes insurance commission cuts
• Wolfe Research Starts Brinks Co. (BCO) at Outperform